| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6018967 | Experimental Neurology | 2012 | 8 Pages |
Abstract
⺠Independent replication of a reported pre-clinical therapy for SCI was achieved. ⺠Documenting pre-clinical drug efficacy depends on the injury model. ⺠Glibenclamide (FDA-approved anti-diabetic drug) could be used for acute SCI therapy.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Phillip G. Popovich, Stanley Lemeshow, John C. Gensel, C. Amy Tovar,